KidneyInternational,Vol.67(2005),pp.2448–2453
Access to, and outcome of, renal transplantation according to
treatment modality of end-stage renal disease in France
YLANACHALEM,JEAN-PHILIPPERYCKELYNCK,PHILIPPETUPPIN,CHRISTIANVERGER,
SYLVIECHAUVE´,andDENISGLOTZ,ONBEHALFOFTHEFRENCHCOLLABORATIVEGROUP
EtablissementFranc¸aisdesGreffes,Paris,France;C.H.U.Clemenceau,Caen,France;C.H.Rene´Dubos,Pontoise,France;Baxter
Healthcare,Maurepas,France;andHoˆpitalSaint-Louis,Paris,France
Accessto,andoutcomeof,renaltransplantationaccordingto 15%inmanyindustrializedcountries,butisonlyaround
treatmentmodalityofend-stagerenaldiseaseinFrance. 10%inFrance[2].
Background.Althoughperitonealdialysis(PD)isrecognized
Foralongtime,manyphysicianshavebeenreluctant
asoneofthemethodsoftreatmentofend-stagerenaldisease
toproposePDtocandidatesforkidneytransplantation.
(ESRD),therehavebeenrecurrentconcernsabouttheaccess
ofpatientstreatedbythismodalitytokidneytransplantation Therehavebeenreportsthattransplantedpatientspre-
(KTx), as well as reports showing increased complications of viouslyonPDhadmorefrequentgraftthrombosis[3,4]
KTxinsuchpatients,suchasgraftthrombosisandinfections. or infections [5] compared to patients treated with HD.
Methods. The aim of this study was to provide a compre-
Whenlookingattransplantationoutcomes,equivalent[6]
hensiveviewoftheimpactontransplantationofpretransplant
orinferiorresults[7]havebeenreportedforPDpatients.
modality of treatment of ESRD using a multivariate analysis
oftheFrenchdatabase.From1997to2000,afterexclusionof However, recent studies have shown that PD is associ-
pediatricpatients,multipletransplantations,andlivingdonors, ated with a lower incidence of post-transplant delayed
6420werepatientsregisteredonthewaitinglist,and3464were graftfunction(DGF)comparedtoHD[8,9].
transplanted.
Althoughtheseconcernsmighthaveadetrimentalim-
Results.UsingaCoxproportionalhazardanalysis,wefound
ashorterwaitingtimeforPDpatients(RR0.71,P<0.0001), pact on the waiting time of PD patients, recent studies
whichbecameequivalenttohemodialysis(HD)patientswhen haveshown,onthecontrary,afasteraccesstotransplan-
takingintoaccountthetransplantcenterasavariable(RR1.0, tationofPDpatients[6,10].
P=0.95).Concerninggraftsurvival,onlypreemptivetransplan-
The relationship between the choice of ESRD treat-
tationhadasignificantimpact,beingassociatedtoadecreased
ment(HD,DP,orPre-T)modality,waitingtime,andgraft
riskofgraftfailure(RR0.46,P=0.005).
survivaldependsonmanyvariables.
Conclusion.Ourstudysupportstheconceptthatthechoiceof
anypretransplantdialysismodalitydoesnotinfluencewaiting The aim of this study was, thus, to evaluate at a na-
timefortransplantortheresultsoftransplantation. tional scale by multivariate analysis the role of ESRD
treatmentonthelikelihoodtoreceiveatransplant(wait-
ingtime),andonpatientandgraftsurvivalsafterkidney
Several renal replacement therapies are available for transplantation.
patients with end-stage renal disease (ESRD), namely
hemodialysis(HD),peritonealdialysis(PD),orpreemp-
tivetransplantation(Pre-T)[1],buttheselectionforany METHODS
givenindividualdependsonmanyvariables,includinghis Patientpopulation
acceptanceoftherapymodalitiesandpretransplantation
In France, it is mandatory to register donors, candi-
strategy.HDisbyfarthemostfrequentmodalityusedfor
dates,aswellasgraftandrecipientfollow-up,inthena-
renal replacement therapy in many countries. The fre-
tionalinformationsystemoftheFrenchTransplantation
quency of patients with ESRD treated by PD reached
Agency(EtablissementFranc¸aisdesGreffes).
Wereviewedthedataofallthepatientsthatwereregis-
teredonthenationalFrenchwaitinglistbetweenJanuary
Keywords:peritonealdialysis,kidneytransplant,graftsurvival,waiting
time. 1997andDecember2000,aswellasallrecipientsofakid-
neygraftduringthesametimeframe.Atotalof6420reg-
ReceivedforpublicationJuly12,2004
istrationsand3464graftsperformedby37centerswere
andinrevisedformOctober27,2004,andDecember22,2004
AcceptedforpublicationJanuary7,2005 finally included in the analysis after exclusion of living
donors, pediatric recipients (<16 years), multiple organ
(cid:1)C 2005bytheInternationalSocietyofNephrology transplants,nonresident,andretransplantregistrations.
2448
Chalemetal:Transplantationaccessandoutcomeaccordingtodialysismodality 2449
Recipientandgraftcriteriaconsideredforadjustment Table 1. Characteristicsofpatientsregisteredonkidneywaitinglist
accordingtotheESRDtreatmentmodality
were:recipientageatregistrationandattransplantation,
gender,bloodgroup,diabetesmellitus,peakpanelreac- PD HD Pre-T
tiveantibody(PRA)level,frequencyofhumanlympho- (N=647) (N=5190) (N=583) Pvalue
cytic antigen (HLA) alleles (with scarcity defined as a Femalegender% 267(41.3) 1910(36.8) 248(42.5) 0.004
frequency <3% among all registered patients), time on Ageyears 44.8±13.2 46.2±12.8 44.8±12.2 0.04
Diabetesmellitus% 17(2.6) 227(4.4) 22(3.8) 0.1
dialysisatregistration,yearofregistration,ESRDtreat-
Yearofregistration%
mentmodalityatregistration,waitingtimebeforetrans- 1997 128(19.8) 1255(24.2) 106(18.2) <0.0001
plantation,HLAmismatching(0–6),coldischemiatime, 1998 167(25.8) 1284(24.7) 113(19.4)
1999 175(27.0) 1388(26.7) 175(30.0)
gender and blood group matching, donor age, gender,
2000 177(27.4) 1263(24.3) 189(32.4)
bloodgroup,andcauseofdeath. Timeondialysisat 11.4±11.8 19.5±34.8 0 <0.0001
registration
months
Statisticalanalysis Bloodgroup%
A 289(44.7) 2173(41.9) 273(46.8) 0.22
TheeffectofESRDtreatmentmodalitywasevaluated AB 24(3.7) 209(4.0) 26(4.5)
ontwomainoutcomes:likelihoodoftransplantationwas B 65(10.0) 563(10.9) 63(10.8)
O 269(41.6) 2245(43.2) 221(37.9)
assessed through the analysis of waiting time to trans- HLAallelesfrequency(<3%)%
plantation and transplant outcome through the analysis 0 179(27.7) 1424(27.4) 184(31.6) 0.02
ofpatientandgraftsurvivals. 1 258(39.9) 1924(37.1) 215(36.9)
2 149(23.0) 1257(24.2) 136(23.3)
Differences among categorized patient’s characteris-
3 54(8.4) 450(8.7) 44(7.5)
ticsweretestedbychi-squaretestfordiscretevariables, ≥4 7(10.0) 135(2.6) 4(0.7)
andanalysisofvariance(ANOVA)forcontinuousvari- PeakPRAlevel%
0–14 598(92.4) 4755(91.6) 542(93.0) 0.6
ables.
15–69 36(5.6) 306(5.9) 32(5.5)
Toestimatewaitingtimetotransplant,timeonthena- 70andabove 13(2.0) 129(2.4) 9(1.5)
tional kidney transplant waiting list was calculated for
Abbreviations are: PRA, panel reactive antibody; Pre-T, preemptive
eachpatient.Theeventofinterestistransplant,withpa- transplantation.Forcontinuousvariables,dataareexpressedasmean±SD.
tientsdyingonthelistcensoredatdateofdeath.Patients
removed from the list were censored at the date of re-
moval,andthosestillawaitingatransplantattheendof feredbetween1997and2000(P<0.0001).Registration
the analysis period were censored at that time. To esti-
of patients treated by PD increased in time, from 128
mategraftsurvivalaftertransplant,definedasapatient
(8.5%) in 1997 to 177 (10.8%) in 2000, as well as Pre-T
alivewithafunctioninggraft,endpointwasdefinedasei-
registrationsfrom106(7.2%)in1997to189(11.3%)in
therdeathorgraftfailure.Kaplan-Meierestimatorswere
2000, while HD decreased (84.3% in 1997 to 77.9% in
usedtodeterminewaitingtimeandgraftsurvival.
2000).
Cox proportional hazard regression was used to ana-
Significant differences between patients according to
lyze the effect of ESRD treatment modality on waiting
ESRD treatment modalities were observed for gender
timeandongraftsurvivaladjustedonallriskfactorsasso- = =
(P 0.004)andageatregistration(P 0.04).Morepre-
ciatedwitheachoutcomeintheunivariateanalysis,with
cisely, PD and Pre-T patients were more often women,
aPvalue<0.2.
andwereregisteredatayoungerage.
Thefinalmultivariablemodelisadjustedoncentersaf-
The overall waiting time curves differed significantly
terinvestigationofapossibleassociationbetweenESRD (P < 0.0001) between ESRD treatment modalities
treatmentmodalitiesandcenterwaitingtimes.Statistical
(Fig. 1), with 13.5 months median waiting time for HD,
significancewasacceptedatP<0.05.
9.4forPD,and11.7forPre-Tpatients(P<0.0001).
AllstatisticalanalyseswereperformedusingSASsoft-
Using the proportional hazard regression model, we
warepackage,version8.1(SASInstitute,Inc.,Cary,NC,
foundanumberofvariablestobesignificantinunivari-
USA).
ateanalysisfortheireffectonwaitingtimebeforetrans-
plantation(Table2).Anincreasedriskwasobservedfor
= =
female gender (RR 1.1, P 0.0003), O and B blood
RESULTS groups[RR= 1.83,P<0.0001,peakPRAlevelbetween
Likelihoodoftransplantation 15% and 69% (RR = 1.42, P < 0.0001) and 70% and
Thecharacteristicsofpatientsatregistrationaresum- more(RR= 2.06,P<0.0001),andanincreasednumber
marized in Table 1. A total of 6240 registrations on the ofinfrequentHLAalleles(RR= 1.2,P <0.0001)].On
waitinglistwereincluded:647(10.1%)PD,5190(80.8%) thecontrary,patientsoflessthan30yearsatregistration
= = =
HD, and 583 (9.1%) Pre-T. The number of new yearly (RR 0.81,P 0.0001),or60yearsandabove(RR
=
registrationsaccordingtoESRDtreatmentmodalitydif- 0.87,P 0.01)hadareducedwaitingtime.
2450 Chalemetal:Transplantationaccessandoutcomeaccordingtodialysismodality
gnitiaw
llitS
%
=
1.0 cipientageabove60yearsattransplantation(RR 2.13,
0.9 P < 0.0001), months on dialysis before transplantation
= = =
0.8 (RR 1.003,P 0.003),andcoldischemictime(RR
0.7 1.02, P = 0.004). Pre-T compared to HD was found to
0.6 betheonlytreatmentmodalitysignificantlylinkedwith
0.5
bettergraftsurvival,andnosignificanteffectongraftsur-
0.4
vivalwasobservedforanydialysismodality.
0.3
Afteradjustmentforriskfactorslinkedwithgraftsur-
0.2
0.1
vivalinunivariateanalysis(P<0.2),PD(RR=
0.90,P
= =
0.0 0.52)hadnoeffectongraftsurvival,butPre-T(RR
0 6 12 18 24 30 36 42 48 0.46, P = 0.005) was still found to be associated with a
Months after registration decreasedriskofgraftfailure.
Concerning patient survival, no difference was found
ESRD treatment modality PD HD Pre T
betweenthedifferentgroupsofpatients(Fig.4).
Fig. 1. Kaplan-Meier plots of waiting time to transplant by ESRD
treatmentmodality(log-rank,P<0.0001).
DISCUSSION
Peritonealdialysisisstillusedinaminorityofpatients
ESRD treatment modality at registration had a pro-
needingrenalreplacementtherapy.Theratesrangefrom
found impact on waiting time, with a risk ratio of 0.71
(P <0.0001)forPDand0.83(P = 0,002)forPre-Tpa- 45% in the United Kingdom to 8% in Germany [2], as
compared to 13% in the United States [11]. However,
tients compared to HD patients. As allocation rules in
thepercentageofpatientswaitingforakidneytransplant
France do not take into account the modality of ESRD
treatedbyPDmaybedifferent,dependingonthechar-
treatment, this prompted us to investigate the potential
acteristics of the patients such as age or comorbidities.
relationshipbetweenwaitingtimeandpercentageofPD
InFrance,nosuchdifferenceexists,asthepercentageof
patients on the waiting list in individual transplant cen-
ESRD patients treated by PD is 10%, and the percent-
ters.ResultsareshowninFigure2,andclearlyshowthat
age of patients on the transplant waiting list treated by
PD patients are more likely to be registered in centers
PD is exactly the same. Transplants from living donors
with the shortest waiting times. Indeed, centers with a
representlessthan5%ofallkidneytransplantationsper-
medianwaitingtimeoflessthan10monthshavethehigh-
formedinFrance.Theproportionofpatientsregistered
est percentage of PD patients on list (16%) compared
onthewaitinglistandexpectingalivingdonortransplant
tothelongerwaitingcenters,averagingonlyaround5%
andtreatedbyPDinFranceis9%,whichiscomparable
PD patients on list. After adjustment on all risk factors
to the percentage of patients registered on the waiting
describedaboveandadjustmentoncenters,noeffectof
listforadeceaseddonor.Moreover,theanalysisofgraft
ESRDtreatmentmodalitywasobservedanylonger,with
= survivalwasperformedonthecohortofpatientsfinally
ariskratioof1.0(P 0.95)forPDmodality(Table2).
transplanted among the cohort of patients included in
theanalysisoftimetotransplantand,therefore,didnot
Two-yeargraftsurvivalaftertransplantation includetheeffectofthedonortype.
The characteristics of donors and recipients at trans- Smalldifferences,however,existintermsofageatreg-
plantation are summarized in Table 3. Of the 3464 istrationandfemalegenderbetweenHDandPDpatients
transplant patients, 400 (11.5%) were treated by PD at (see Table 1). PD patients are more likely to be female
registration, 2738 (79.1%) by HD, and 326 (9.4%) by andyounger,asseenintheUnitedStates[8].
Pre-T. The same differences seen in registered patients The likelihood of transplantation for PD patients has
in terms of age and gender between ESRD treatment recentlybeenreportedas1.39timesgreaterthanHDpa-
modalities are again observed in transplanted patients tientsinaretrospectiveanalysisoftheUNOSdatabase
(Table 1). The unadjusted overall graft survival differs [11],evenafterconsideringclinicaldifferencesbetween
=
significantly (P 0.003) according to ESRD treatment HDandPDpatients,suchassex,race,age,BMI,andco-
modality (Fig. 3). Pre-T graft survival was significantly morbidities.Likewise,inouranalysis,wefoundareduced
=
higher when compared to HD (P 0.0009) and to PD median waiting time to transplantation for PD patients
=
graftsurvival(P 0.02).Nodifferencewasobservedbe- (Fig.1)thatpersistedaftertakingintoaccountsuchvari-
=
tweenHDandPDpopulations(P 0.31). ablesasgender,age,orPRAlevel.However,thisresult
Using the proportional hazard regression model, we couldnotbeeasilyexplained,askidneyallocationrules
found different variables to be significant in univariate in France are blind to dialysis modality. As the median
analysisfortheireffectongraftsurvival(Table4),such waitingtimedifferssignificantlybetweentransplantcen-
asdonorageabove54years(RR= 1.66,P<0.0001),re- tersinFrance[12],wehypothesizedthatacentereffect
Chalemetal:Transplantationaccessandoutcomeaccordingtodialysismodality 2451
Table 2. Coxunivariateandmultivariateanalysisofwaitingtimetotransplant(N=6420registrations)
Multivariate
Univariate Multivariate (adjustedoncentereffect)
HR(95%CI) Pvalue HR(95%CI) Pvalue HR(95%CI) Pvalue
Yearofregistration(1997,referent) 1.06(1.02,1.01) 0.001 1.08(1.04,1.12) <0.0001 1.08(1.04,1.1) <0.0001
Femalegender 1.1(1.06,1.2) 0.0003 1.1(1.00,1.15) 0.053 1.056(0.99,1.14) 0.08
Ageatregistrationyears
16–29 0.81(0.73,0.9) <0.0001 0.83(0.75,0.9) 0.0004 0.89(0.8,0.99) 0.03
30–44,referent
45–59 0.95(0.82,1.03) 0.2 0.96(0.89,1.04) 0.33 0.95(0.88,1.03) 0.22
60andolder 0.87(0.78,0.87) 0.01 0.87(0.78,0.97) 0.01 0.9(0.80,0.99) 0.04
Bloodgroup(OandB) 1.83(1.65,1.87) <0.0001 1.84(1.72,1.97) <0.0001 1.96(1.84,2.10) <0.0001
PeakPRAlevel%
0–14,referent
15–69 1.42(1.23,1.65) <0.0001 1.40(1.20,1.63) <0.0001 1.7(1.46,1.98) <0.0001
70andabove 2.06(1.6,2.68) <0.0001 2.11(1.6,2.75) <0.0001 3.0(2.3,3.97) <0.0001
HLAallelefrequency<3% 1.2(1.14,1.22) <0.0001 1.2(1.13,1.21) <0.0001 1.2(1.13,1.21) <0.0001
Timeondialysisatregistration
<19months,referent
≥19months 1.1(1.03,1.2) 0.009 1.02(0.94,1.1) 0.58 1.03(0.95,1.12) 0.45
ESRDtreatmentmodality
Hemodialysis,referent
Peritonealdialysis 0.71(0.64,0.79) <0.0001 0.71(0.64,0.79) <0.0001 1.00(0.90,1.12) 0.95
Preemptivetransplantation 0.83(0.74,0.94) 0.002 0.86(0.76,0.96) 0.009 0.92(0.81,1.03) 0.15
Abbreviationsare:PRA,panelreactiveantibody;HR,hazardratio.
20%
15%
10%
5%
0%
deretsiger
DP
%
Table 3. CharacteristicsofdonorsandrecipientsaccordingtoESRD
treatmentmodality(N=3464recipients)
16%
Peritoneal
dialysis Hemodialysis Pre-T
(N=400) (N=2738) (N=326) Pvalue
Donorageyears 40.8±13.8 40.77±14.5 39.6±15.3 0.4
6% 5% HLAmismatches 3.2±1.2 3.1±1.22 3.0±1.2 0.14
Coldischemictime 20.5±8.1 22.4±8.3 22.5±8.4 <0.0001
hours
Femalegender 156(39.0) 966(35.3) 141(43.2) 0.01
Recipientageyears 45.2±13.1 46.6±12.9 44.8±12.4 0.012
0-10 11-20 21+ Timeondialysis 18.6±13.0 26.7±33.9 –
Median waiting time, months months
Diabetesmellitus 9(2.3) 101(3.7) 11(3.4) 0.3
PeakPRAlevel%
Fig. 2. Proportion of PD registrations according to median waiting
0–14 380(95) 2548(92.9) 304(93.3) 0.5
timetotransplant.
15–69 13(3.3) 146(5.3) 18(5.5)
70andabove 7(1.6) 44(1.6) 4(1.2)
Abbreviations are: PRA, panel reactive antibody, Pre-T, preemptive
couldberesponsibleforthisapparentdifferenceinwait- transplantation.Forcontinuousvariables,dataareexpressedasmean±SD.
ingtimebetweenPDandHDpatients.We,thus,divided
thetransplantgroupsintoshort,medium,orlongwaiting
time, and assessed the proportion of PD patients regis-
tered in those three types of centers (Fig. 2). There is trationandtheactualwaitingtimefortransplant.Inour
a striking difference, with a much higher proportion of series, PD patients were registered significantly earlier
PDpatientsinthecenterswiththelowestmedianwait- than other patients (11.4 vs. 19.5 months, P < 0.0001).
ingtime.Wethenestimatedwaitingtimeintegratingthe ThisleadstoashorterdialysistimeforPDpatients,even
center as a variable, which became strictly identical be- withequivalentwaitingtimes.Thismightexplainthere-
tweendialysismodalities.Thispotentialbiascouldcasta sultsofpreviouslypublishedstudieswithlongerdialysis
doubtonpreviouspublications,demonstratingashorter durationforHDpatients[6,10,14].
waitingtimeofPDpatients. Graftsurvivalinouranalysisdoesnotdependondial-
Our analysis points out to another potential bias, ysis modality, but is strongly enhanced by preemptive
namely pretransplant dialysis duration. Indeed, it has transplantation,inaccordancewithpreviouslypublished
been demonstrated that dialysis duration impacts neg- studies[15–17].Althoughourdatabasedoesnotinclude
atively on graft survival [13]. This period of time is, in complicationssuchasthrombosisorrejections,thesim-
fact, the sum of the time spent on dialysis before regis- ilar survival suggests that any potential complication
2452 Chalemetal:Transplantationaccessandoutcomeaccordingtodialysismodality
Table 4. Univariateandmultivariateanalysisofgraftsurvival
Univariate Multivariate
HR(95%CI) Pvalue HR(95%CI) Pvalue
Predictor
Donorageyears
0–15 1.24(0.66,2.34) 0.5 1.23(0.64,2.34) 0.53
16–54,referent
55andolder 1.66(1.29,2.12) <0.0001 1.45(1.1,1.91) 0.008
Donordeath:CVAorstroke 1.16(0.93,1.44) 0.19 1.02(0.80,1.28) 0.89
Timeondialysismonths 1.003(1.001,1.005) 0.003 1.002(1.00,1.004) 0.09
Coldischemictimehours 1.02(1.01,1.03) 0.0042 1.016(1.003,1.03) 0.001
Recipient-donorbloodgroupmismatch 1.47(0.86,2.5) 0.16 1.53(0.88,2.65) 0.13
NumberofHLAmismatches(A-B-DR) 1.05(0.96,1.5) 0.26 1.06(0.9702,1.16) 0.22
Femaledonortomalerecipient 1.08(0.84,1.40) 0.56 -
Recipientageattransplantationyears
16–29 1.17(0.8,1.7) 0.42 1.21(0.83,1.78) 0.32
30–44,referent
45–59 1.2(0.90,1.61) 0.22 1.13(0.84,1.51) 0.44
≥60 2.13(1.54,2.9) <0.0001 1.85(1.32,2.56) 0.0003
Diabetesmellitus 1.20(0.69,2.08) 0.5 -
PeakPRAlevel%
0–14,referent
15–69 1.47(0.96,2.25) 0.076 1.40(0.91,2.14) 0.134
70andabove 0.99(0.41,2.38) 0.97 1.0(0.996,2.46) 0.99
Dialysismodality
Hemodialysis,referent
Peritonealdialysis 0.83(0.58,1.19) 0.31 0.90(0.62,1.28) 0.52
Preemptivetransplantation 0.413(0.242,0.71) 0.0013 0.46(0.27,0.79) 0.005
Abbreviationsare:PRA,panelreactiveantibody,HR,hazardratio.
1.0
0.9
0.8
0.7
0.6
0.5
%
,lavivruS
1.0
0.9
0.8
0.7
0.6
0.5
0 6 12 18 24
Months of follow-up
ESRD treatment modality PD HD Pre T
Months after transplant % Survival (number of events)
3 months 95.7 (17) 94.6 (145) 97.5 (8)
6 months 93.1 (27) 93.3 (181) 96.6 (11)
12 months 92.1 (31) 92.1 (212) 96.0 (13)
24 months 91.3 (34) 89.5 (275) 95.6 (14)
Fig. 3. Kaplan-MeierplotsofkidneygraftsurvivalbyESRDtreatment
modality(LogRank,P=0.003).
arising in the PD patients has no detrimental effect on
patientorgraftsurvivalattwoyears[6,11].
CONCLUSION
Ourstudysupportstheconceptthatthechoiceofdial-
ysismodalitydoesnotinfluenceeitherthepatientwaiting
timefortransplantationorpatientandgraftsurvival.
%
,lavivruS
0 6 12 18 24
Months of follow-up
ESRD treatment modality PD HD Pre-T
Fig. 4. Kaplan-Meier plots of patient survival by ESRD treatment
modality(LogRank,P=0.09).
ACKNOWLEDGMENTS
The authors would like to thank the kidney trans-
plant teams of the following hospitals for providing us
their data: Hoˆpital Sud, Amiens, Hoˆpital Hoˆtel-Dieu,
Angers,HoˆpitalSaint-Jacques,Besanc¸on,HoˆpitalPelle-
grin,Bordeaux,HoˆpitallaCavaleBlanche,Brest,Hoˆpital
Clemenceau, Caen, Hoˆpital G. Montpied, Clermont-
Ferrand, Hoˆpital du Bocage, Dijon, Hoˆpital Necker,
Paris, Hoˆpital Tenon, Paris, Hoˆpital Saint-Louis, Paris,
Hoˆpital A. Michalon, Grenoble, Hoˆpital C. Huriez,
Lille, Hoˆpital Dupuytren, Limoges, Hoˆpital E. Herriot,
Lyon,HoˆpitalLyon-sud,Lyon,HoˆpitaldelaConception,
Chalemetal:Transplantationaccessandoutcomeaccordingtodialysismodality 2453
Marseille, Hoˆpital Lapeyronie, Montpellier, Hoˆpital postoperativeinfectionsassociatedwithperitonealdialysisinrenal
Brabois, Nancy, Hoˆpital Pasteur, Nice, Hoˆpital Hoˆtel- transplantrecipients.Transplantation68:535–540,1999
Dieu,Nantes,HoˆpitalFoch,Suresnes,HoˆpitalEurope´en
6.O’DONOGHUED,MANOSJ,PEARSONR,etal:Continuousambulatory
peritonealdialysisandrenaltransplantation:Aten-yearexperience
G.Pompidou,Paris,HoˆpitalH.Mondor,Cre´teil,Hoˆpital inasinglecenter.PeritDialInt12:242,245–249,1992
delaPitie´-Salpeˆtrie`re,Paris,HoˆpitaldeBiceˆtre,Kremlin 7.GUILLOUPJ,WILLEJ,DAVISONAM,etal:CAPD—Ariskfactorin
renaltransplantation?BrJSurg71:878–880,1984
Biceˆtre, Hoˆpital J. Bernard, Poitiers, Hoˆpital F. Guyon,
8.BLEYERAJ,BURKARTJM,RUSSELLGB,etal:Dialysismodalityand
La Re´union, Hoˆpital de Pontchaillou, Rennes, Hoˆpital delayedgraftfunctionaftercadavericrenaltransplantation.JAm
Maison Blanche, Reims, Hoˆpital C. Nicolle, Rouen, SocNephrol10:154–159,1999
Hoˆpital Nord, Saint-Etienne, Hospices Civils, Stras-
9.VANBIESENW,VANHOLDERR,VANLOOA,etal:Peritonealdialysis
favorablyinfluencesearlygraftfunctionafterrenaltransplantation
bourg,HoˆpitalRangueil,Toulouse,HoˆpitalBretonneau, comparedtohemodialysis.Transplantation69:508–514,2000
Tours. 10.JOSEPH JT, JINDAL RM: Influence of dialysis on post-transplant
events.ClinTransplant16:18–23,2002
ReprintrequeststoDenisGlotz,HoˆpitalEurope´enGeorgesPompi- 11.SNYDER JJ, KASISKE BL, GILBERTSON DT, et al: A comparison of
dou,20rueLeblanc,75015,Paris,France. transplantoutcomesinperitonealandhemodialysispatients.Kid-
E-mail:denis.glotz@sls.ap-hop-paris.fr neyInt62:1423–1430,2002
12.CONSEILME´DICALETSCIENTIFIQUE:Lepre´le´vementetlagreffeen
France,Paris,EtablissementFrancaisdesGreffes,1997
REFERENCES
13.MEIER-KRIESCHE HU, PORT FK, OJO AO, et al: Effect of waiting
1.MOELLERS,GIOBERGES,BROWNG:ESRDpatientsin2001:Global timingtimeonrenaltransplantoutcome.KidneyInt58:1311–1317,
overviewofpatients,treatmentmodalitiesanddevelopmenttrends. 2000
NephrolDialTransplant17:2071–2076,2002 14.PEREZ FONTAN M, RODRIGUEZ-CARMONA A, GARCIA FALCON T,
2.MIGNON F, MICHEL C, VIRON B: Why so much disparity et al: Peritoneal dialysis is not a risk factor for primary vascular
of PD in Europe? Nephrol Dial Transplant 13:1114–1117, graftthrombosisafterrenaltransplantation.PeritDialInt18:311–
1998 316,1998
3.MCDONALDRA,SMITHJM,STABLEIND,etal:Pretransplantperi- 15.PAPALOISVE,MOSSA,GILLINGHAMKJ,etal:Pre-emptivetrans-
toneal dialysis and graft thrombosis following pediatric kidney plantsforpatientswithrenalfailure:Anargumentagainstwaiting
transplantation:ANAPRTCSreport.PediatrTransplant7:204–208, untildialysis.Transplantation70:625–631,2000
2003 16.ASDERAKIS A, AUGUSTINE T, DYER P, et al: Pre-emptive kidney
4.MURPHYBG,HILLCM,MIDDLETOND,etal:Increasedrenalallograft transplantation:Theattractivealternative.NephrolDialTransplant
thrombosis in CAPD patients. Nephrol Dial Transplant 9:1166– 13:1799–1803,1998
1169,1994 17.HAKIMNS,BENEDETTIE,PAYNEWD,etal:Pre-emptiverenaltrans-
5.PASSALACQUAJA,WILANDAM,FINKJC,etal:Increasedincidenceof plantation.IntSurg83:330–332,1998
